BIO-TECHNE Corp Deferred Revenue Recognized
BIO-TECHNE Corp (TECH) reported Deferred Revenue Recognized of $29.60 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-24
- BIO-TECHNE Corp contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $4.70M, a 17.50% increase year-over-year.
- BIO-TECHNE Corp contract with customer, liability, revenue recognized for the quarter ending 2025-12-31 was $9.40M, a 17.50% increase year-over-year.
- BIO-TECHNE Corp contract with customer, liability, revenue recognized for the quarter ending 2025-09-30 was $13.20M, a 11.86% increase year-over-year.
- BIO-TECHNE Corp contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $4.00M, a 25.00% increase year-over-year.
- BIO-TECHNE Corp contract with customer, liability, revenue recognized for fiscal 2026 was $29.60M, a 12.98% increase from fiscal 2025.
- BIO-TECHNE Corp contract with customer, liability, revenue recognized for fiscal 2025 was $26.20M, a 25.36% increase from fiscal 2024.
- BIO-TECHNE Corp contract with customer, liability, revenue recognized for fiscal 2024 was $20.90M, a 2.79% decline from fiscal 2023.
- BIO-TECHNE Corp contract with customer, liability, revenue recognized for fiscal 2023 was $21.50M, a 27.22% increase from fiscal 2022.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.60M 10-K · filed 2026-08-24 | |||
| 2026-03-31 | $4.70M 10-Q · filed 2026-05-06 | $27.30M 10-Q · filed 2026-05-06 | ||
| 2025-12-31 | $9.40M 10-Q · filed 2026-02-04 | $22.60M 10-Q · filed 2026-02-04 | ||
| 2025-09-30 | $13.20M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $26.20M 10-K · filed 2026-08-24 | |||
| 2025-03-31 | $4.00M 10-Q · filed 2026-05-06 | $23.80M 10-Q · filed 2026-05-06 | ||
| 2024-12-31 | $8.00M 10-Q · filed 2026-02-04 | $19.90M 10-Q · filed 2026-02-04 | ||
| 2024-09-30 | $11.80M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $20.90M 10-K · filed 2025-08-22 | |||
| 2024-03-31 | $3.20M 10-Q · filed 2025-05-08 | $19.50M 10-Q · filed 2025-05-08 | ||
| 2023-12-31 | $7.10M 10-Q · filed 2025-02-06 | $18.80M 10-Q · filed 2025-02-06 | ||
| 2023-09-30 | $11.80M 10-Q · filed 2024-11-05 | |||
| 2023-06-30 | $21.50M 10-K · filed 2024-08-22 | |||
| 2023-03-31 | $3.60M 10-Q · filed 2023-05-08 | $19.50M 10-Q · filed 2023-05-08 | ||
| 2022-12-31 | $5.30M 10-Q · filed 2023-02-07 | $15.90M 10-Q · filed 2023-02-07 | ||
| 2022-09-30 | $10.60M 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $16.90M 10-K · filed 2022-08-24 | |||
| 2022-03-31 | $1.90M 10-Q · filed 2022-05-09 | $15.20M 10-Q · filed 2022-05-09 | ||
| 2021-12-31 | $3.60M 10-Q · filed 2022-02-07 | $13.30M 10-Q · filed 2022-02-07 | ||
| 2021-09-30 | $9.70M 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $10.60M 10-K · filed 2021-08-25 | |||
| 2021-03-31 | $1.60M 10-Q · filed 2021-05-07 | $9.70M 10-Q · filed 2021-05-07 | ||
| 2020-12-31 | $3.40M 10-Q · filed 2021-02-08 | $8.10M 10-Q · filed 2021-02-08 | ||
| 2020-09-30 | $4.80M 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $7.60M 10-K · filed 2020-08-26 | |||
| 2020-03-31 | $1.10M 10-Q · filed 2020-05-11 | $7.00M 10-Q · filed 2020-05-11 | ||
| 2019-12-31 | $2.20M 10-Q · filed 2020-02-06 | $6.00M 10-Q · filed 2020-02-06 | ||
| 2019-09-30 | $3.80M 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | $7.00M 10-K/A · filed 2019-11-06 | |||
| 2019-03-31 | $900.00K 10-Q · filed 2019-05-07 | $6.50M 10-Q · filed 2019-05-07 | ||
| 2018-12-31 | $2.00M 10-Q · filed 2019-02-07 | $5.60M 10-Q · filed 2019-02-07 | ||
| 2018-09-30 | $3.80M 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |